Piper Sandler Maintains Overweight on Revance Therapeutics, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem maintains an Overweight rating on Revance Therapeutics (NASDAQ:RVNC) but lowers the price target from $11 to $6.
August 09, 2024 | 2:05 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Piper Sandler maintains an Overweight rating on Revance Therapeutics but lowers the price target from $11 to $6.
The lowered price target from $11 to $6 suggests a less optimistic outlook for Revance Therapeutics, which could negatively impact investor sentiment and short-term stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100